Literature DB >> 25038189

Promotion of lung tumor growth by interleukin-17.

Beibei Xu1, James F Guenther1, Derek A Pociask2, Yu Wang1, Jay K Kolls2, Zongbing You3, Bysani Chandrasekar4, Bin Shan5, Deborah E Sullivan6, Gilbert F Morris7.   

Abstract

Recent findings demonstrate that inhaled cigarette smoke, the predominant lung carcinogen, elicits a T helper 17 (Th17) inflammatory phenotype. Interleukin-17A (IL-17), the hallmark cytokine of Th17 inflammation, displays pro- and antitumorigenic properties in a manner that varies according to tumor type and assay system. To investigate the role of IL-17 in lung tumor growth, we used an autochthonous tumor model (K-Ras(LA1) mice) with lung delivery of a recombinant adenovirus that expresses IL-17A. Virus-mediated expression of IL-17A in K-Ras(LA1) mice at 8-10 wk of age doubled lung tumor growth in 3 wk relative to littermates that received a green fluorescent protein-expressing control adenovirus. IL-17 induced matrix metalloproteinase-9 (MMP-9) expression in vivo and in vitro. In accord with this finding, selective and specific inhibitors of MMP-9 repressed the increased motility and invasiveness of IL-17-treated lung tumor cells in culture. Knockdown or mutation of p53 promoted the motility of murine lung tumor cells and abrogated the promigratory role of IL-17. Coexpression of siRNA-resistant wild-type, but not mutant, human p53 rescued both IL-17-mediated migration and MMP-9 mRNA induction in p53 knockdown lung tumor cells. IL-17 increased MMP-9 mRNA stability by reducing interaction with the mRNA destabilizing serine/arginine-rich splicing factor 1 (SRSF1). Taken together, our results indicate that IL-17 stimulates lung tumor growth and regulates MMP-9 mRNA levels in a p53- and SRSF1-dependent manner.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  IL-17; MMP-9; SRSF1; lung tumor growth; p53

Mesh:

Substances:

Year:  2014        PMID: 25038189      PMCID: PMC4166785          DOI: 10.1152/ajplung.00125.2014

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  80 in total

1.  Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.

Authors:  Zdenka Navratilova; Jaromir Zatloukal; Eva Kriegova; Vitezslav Kolek; Martin Petrek
Journal:  Respirology       Date:  2012-08       Impact factor: 6.424

Review 2.  Targeting IL-17 and TH17 cells in chronic inflammation.

Authors:  Pierre Miossec; Jay K Kolls
Journal:  Nat Rev Drug Discov       Date:  2012-10       Impact factor: 84.694

3.  The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis.

Authors:  J Oh; R Takahashi; S Kondo; A Mizoguchi; E Adachi; R M Sasahara; S Nishimura; Y Imamura; H Kitayama; D B Alexander; C Ide; T P Horan; T Arakawa; H Yoshida; S Nishikawa; Y Itoh; M Seiki; S Itohara; C Takahashi; M Noda
Journal:  Cell       Date:  2001-12-14       Impact factor: 41.582

Review 4.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

5.  Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.

Authors:  S Ylisirniö; M Höyhtyä; T Turpeenniemi-Hujanen
Journal:  Anticancer Res       Date:  2000 Mar-Apr       Impact factor: 2.480

6.  Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.

Authors:  Sergei I Grivennikov; Kepeng Wang; Daniel Mucida; C Andrew Stewart; Bernd Schnabl; Dominik Jauch; Koji Taniguchi; Guann-Yi Yu; Christoph H Osterreicher; Kenneth E Hung; Christian Datz; Ying Feng; Eric R Fearon; Mohamed Oukka; Lino Tessarollo; Vincenzo Coppola; Felix Yarovinsky; Hilde Cheroutre; Lars Eckmann; Giorgio Trinchieri; Michael Karin
Journal:  Nature       Date:  2012-11-08       Impact factor: 49.962

Review 7.  Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells.

Authors:  Nasr Y A Hemdan
Journal:  Immunol Lett       Date:  2012-11-15       Impact factor: 3.685

8.  Suppression of cell invasion and migration by propofol are involved in down-regulating matrix metalloproteinase-2 and p38 MAPK signaling in A549 human lung adenocarcinoma epithelial cells.

Authors:  King-Chuen Wu; Su-Tso Yang; Te-Chun Hsia; Jai-Sing Yang; Shang-Ming Chiou; Chi-Cheng Lu; Rick Sai-Chuen Wu; Jing-Gung Chung
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

9.  miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.

Authors:  Andrea L Kasinski; Frank J Slack
Journal:  Cancer Res       Date:  2012-09-10       Impact factor: 12.701

10.  IL-17 promoted metastasis of non-small-cell lung cancer cells.

Authors:  Qinchuan Li; Yang Han; Guangru Fei; Zhongliang Guo; Tao Ren; Zhongmin Liu
Journal:  Immunol Lett       Date:  2012-10-23       Impact factor: 3.685

View more
  21 in total

1.  Role of p53 in the chronic pulmonary immune response to tangled or rod-like multi-walled carbon nanotubes.

Authors:  Katherine S Duke; Elizabeth A Thompson; Mark D Ihrie; Alexia J Taylor-Just; Elizabeth A Ash; Kelly A Shipkowski; Jonathan R Hall; Debra A Tokarz; Mark F Cesta; Ann F Hubbs; Dale W Porter; Linda M Sargent; James C Bonner
Journal:  Nanotoxicology       Date:  2018-10-14       Impact factor: 5.913

Review 2.  IL-17 in the lung: the good, the bad, and the ugly.

Authors:  Stephen J Gurczynski; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

3.  IL-21 polymorphisms rs907715 and rs2221903 are associated with decreased non-small cell lung cancer susceptibility.

Authors:  Lanping Liu; Fang Shi; Shanshan Li; Xiuju Liu; Lili Wei; Jian Zhang; Xiao Ju; Jinming Yu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth.

Authors:  Cornelia Voigt; Peter May; Adrian Gottschlich; Anamarija Markota; Daniel Wenk; Inga Gerlach; Sebastian Voigt; Georgios T Stathopoulos; Kristina A M Arendt; Constanze Heise; Felicitas Rataj; Klaus-Peter Janssen; Melanie Königshoff; Hauke Winter; Isabelle Himsl; Wolfgang E Thasler; Max Schnurr; Simon Rothenfußer; Stefan Endres; Sebastian Kobold
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-17       Impact factor: 11.205

5.  Genetic alterations of interleukin-17 and related genes in human prostate cancer.

Authors:  Ruoxin Lan; Kun Zhang; Tianhua Niu; Zongbing You
Journal:  Am J Clin Exp Urol       Date:  2019-12-15

6.  Expression levels of IL-17 and TNF-α in degenerated lumbar intervertebral discs and their correlation.

Authors:  Xiao-Gang Liu; Hong-Wei Hou; Yi-Lin Liu
Journal:  Exp Ther Med       Date:  2016-04-11       Impact factor: 2.447

7.  IL-17A Promotes Intracellular Growth of Mycobacterium by Inhibiting Apoptosis of Infected Macrophages.

Authors:  Andrea Cruz; Paula Ludovico; Egidio Torrado; José Bernardo Gama; Jeremy Sousa; Joana Gaifem; Rui Appelberg; Fernando Rodrigues; Andrea M Cooper; Jorge Pedrosa; Margarida Saraiva; António G Castro
Journal:  Front Immunol       Date:  2015-09-30       Impact factor: 7.561

8.  Human colon carcinogenesis is associated with increased interleukin-17-driven inflammatory responses.

Authors:  Zhaohui Xie; Yine Qu; Yanli Leng; Wenxiu Sun; Siqi Ma; Jingbo Wei; Jiangong Hu; Xiaolan Zhang
Journal:  Drug Des Devel Ther       Date:  2015-03-18       Impact factor: 4.162

9.  Hyperinsulinemia enhances interleukin-17-induced inflammation to promote prostate cancer development in obese mice through inhibiting glycogen synthase kinase 3-mediated phosphorylation and degradation of interleukin-17 receptor.

Authors:  Sen Liu; Qiuyang Zhang; Chong Chen; Dongxia Ge; Yine Qu; Rongyi Chen; Yi-Ming Fan; Nan Li; Wendell W Tang; Wensheng Zhang; Kun Zhang; Alun R Wang; Brian G Rowan; Steven M Hill; Oliver Sartor; Asim B Abdel-Mageed; Leann Myers; Qishan Lin; Zongbing You
Journal:  Oncotarget       Date:  2016-03-22

10.  IL-17A-producing T cells are associated with the progression of lung adenocarcinoma.

Authors:  Zhang Bao; Guohua Lu; Dawei Cui; Yinan Yao; Guangdie Yang; Jianying Zhou
Journal:  Oncol Rep       Date:  2016-05-27       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.